Saturday 17 October 2026
Export IRON’s income statement to Excel — free account
Disc Medicine, Inc.
IRON Healthcare Biotechnology
In the quarter to June 2026, EPS grew 2.53%, free cash flow grew 7.83% and total debt rose 106.5%, each against the same quarter a year earlier.
56.80
0.15
+0.26%
Follow IRON
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '20 | Jan '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
21.94 | 21.17 | 17.06 | 8.79 | 8.79 | 6.74 | 6.74 | 0.20 | 0.20 | — |
Net Debt/EBITDA |
3.12 | 3.42 | 3.96 | 4.11 | 0.00 | 2.84 | 0.00 | (0.16) | (0.51) | — |
Debt/Assets |
3.61% | 5.70% | 0.00% | 0.00% | 0.00% | 0.44% | 0.00% | 119.62% | 260.13% | 0.00% |
Debt/Equity |
0.04 | 0.06 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | (0.46) | (0.99) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.85 | 0.86 | 0.96 | 0.90 | 0.90 | 0.77 | 0.77 | 0.80 | 0.80 | — |
Capex/Depreciation |
0.11 | 0.10 | (0.89) | (1.70) | 0.00 | (2.12) | 0.00 | (0.07) | 0.00 | — |
Interest Coverage |
(65.43) | (226.78) | — | — | 0.00 | (14.33) | 0.00 | (4.99) | (44.16) | — |
| (35.86%) | (27.73%) | (29.30%) | (83.32%) | 0.00% | 83.59% | 0.00% | 186.80% | 0.00% | — | |
| (32.55%) | (25.29%) | (26.90%) | (32.01%) | 0.00% | (71.42%) | 0.00% | (490.89%) | 0.00% | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(27.61%) | (23.22%) | (22.19%) | (26.59%) | (26.38%) | (46.61%) | (45.64%) | 209.24% | 209.24% | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | — | 0.00% | — | — |
Free Cash Flow per Share |
(5.14) | (3.42) | (3.30) | (40.81) | (40.65) | (31.44) | (31.35) | (21.65) | (21.64) | — |
Cash per Share |
22.42 | 17.75 | 16.15 | 187.31 | 187.39 | 100.27 | 100.42 | 2.98 | 2.98 | — |
Shareholders Equity per Share |
20.96 | 16.07 | 15.47 | 169.97 | 169.89 | (73.12) | 88.40 | (14.46) | (14.46) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
20.96 | 16.07 | 15.47 | 169.97 | 169.89 | (73.12) | 88.40 | (14.46) | (14.46) | — |
Free Cash Flow |
(181.33) | (94.43) | (73.55) | (42.40) | (42.25) | (27.60) | (27.53) | (32.73) | (32.71) | — |
Working Capital |
767.26 | 470.30 | 344.22 | 175.91 | 175.91 | 77.06 | 77.06 | (19.81) | (19.81) | — |
Capital Expenditures |
(0.93) | (0.50) | (0.09) | (0.15) | (0.15) | (0.07) | (0.07) | (0.02) | (0.02) | — |
Net Current Asset Value |
736.85 | 440.43 | 342.79 | 174.89 | 174.89 | (66.13) | 75.73 | (25.11) | (25.11) | — |
| Other line items | ||||||||||
Quick Ratio |
21.59 | 21.01 | 16.81 | 8.62 | 8.63 | 6.56 | 6.57 | 0.18 | 0.18 | — |
Depreciation/Fixed assets |
(7.11) | (6.85) | 0.59 | 0.53 | 0.19 | 0.30 | 0.11 | 1.10 | 1.10 | — |
Cash ROIC |
(11.62%) | (9.82%) | (10.43%) | (11.42%) | 0.00% | (113.88%) | 0.00% | 441.88% | (763.85%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | — | 0.00 | — | 0.00 | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | — | 0.00 | — | 0.00 | — | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(5.11) | (3.40) | (3.29) | (40.67) | (40.65) | (31.36) | (31.35) | (21.64) | (21.64) | — |
Capex per Share |
(0.03) | (0.02) | 0.00 | (0.15) | 0.00 | (0.08) | 0.00 | (0.01) | 0.00 | — |
Average Payables |
8.48 | 10.29 | 14.40 | 9.36 | 9.36 | 2.47 | 2.47 | 2.38 | 2.38 | — |
Average Assets |
651.83 | 432.38 | 284.10 | 146.31 | 146.31 | 50.37 | 50.37 | 8.32 | 4.16 | 0.00 |
Average Common Equity |
591.71 | 394.35 | 260.86 | 56.20 | 56.20 | (43.03) | (43.03) | (21.86) | (21.86) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | — | — |
Columns are period end dates